Qiagen Building Sample-Prep Tech for Colorectal Cancer Test Under Epigenomics Option
March 03, 2011
Qiagen Building Sample-Prep Tech for Colorectal Cancer Test Under Epigenomics Option
The deal makes Qiagen the latest company to work with Epigenomics to craft a test based on mSEPT9. Qiagen hopes to distinguish itself, however, by developing a new front-end sample-prep technology that will optimize the test for use on its QIAsymphony automated modular testing platform.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- ARUP Launches Blood-Based LDT for Colorectal Cancer in US Based on Epigenomics' Septin9 Biomarker
July 22, 2010 / PCR Insider - Epigenomics Taps Synlab to Provide Colorectal Cancer Dx in Europe; Completes $44.2M Financing
April 8, 2010 / PCR Insider - Epigenomics Taps Pronto Diagnostics as Israeli Distributor for Colorectal Cancer Dx
October 14, 2010 / PCR Insider - Epigenomics Preps for European Launch of RT-PCR Lung Cancer Dx after Clinical Trial Validation
June 24, 2010 / PCR Insider - Qiagen Expands Companion Dx Portfolio with Three Licensing Deals; Exceeds 2012 QiaSymphony Placement Target
January 7, 2013 / GenomeWeb Daily News